biota has a massive pr problem !!, page-3

There are two problems with LANI:

1. It was not discovered in the US. The "not invented here" issue is a big problem. The people hyping peramivir are mainly US brokers. Australian brokers, as we have seen, are very, very conservative and their reports have almost no LANI sales built into their forcasts.

Today's announcement of an order for 1,000 - 40,000 doses of peramivir is pathetic (equal to roughly 10 min to 7 hours production at the old figure of 50m per year). To cover their overvaluing the company they say that the price will be 10x that of tamiflu and relenza. The amount is still pathetic at $0.3m - $14m. Expect their sp to fall dramatically.

2. You are dealing with an equal JV between BTA and DS. Having worked with Asian J Ventures before I know that trying to get them to agree with anything takes a lot of time. Given the size of DS (it is Japan’s largest pharmaceutical company), there may not be any advantage in it for DS to hype LANI. The management/directors may not get options and they probably have a job for life.

You are right, LANI is under publicised to BTA's detriment. When is the next annual meeting?


M